Regis Technologies Opens Pharmaceutical Manufacturing Center In Morton Grove, Illinois
The company spent two years constructing the suite and preparing its team for the new potent compound capabilities. The PCS addition provides for small molecule cGMP manufacturing of potent compounds up to about one kilogram per batch. PCS targets small molecule oncologicals and linker payload projects for antibody drug conjugates.
According to company officials, Regis invested in this project to extend their custom cGMP offerings to the oncology market. The new PCS will also provide new avenues of career development for its staff.
Director of Business Development, Wayne Nowicki, said, “We see the PCS as an important asset to serve the growing oncology market as more companies look to advance their lead candidates into the clinic.”
Regis’ Manager of Process Engineering, Dragan Ristic, supervised the design and construction of the suite. Proper handling of potent compounds requires the use of specialized facilities that are carefully designed to minimize containment risks. Regis’ new PCS includes isolators, laminar flow hoods and local exhaust ventilation appropriate for potent compound handling, company officials said.
Supply Chain Bottlenecks Creating New “Logistical Hotspots”
The “Great Resignation” Is Impacting Corporate Relocations
Workforce Q4 2021
Changes in the Incentives Landscape
2020 Top States for Doing Business Showcase Their Pro-Business Environments
2021 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
How an International Business Can Enter the U.S. Market Via M&A